Humoral and cellular response to influenza vaccine in HIV-infected children with full viroimmunologic response to antiretroviral therapy

Alessandra Viganò, Gian Vincenzo Zuccotti, Michela Pacei, Paola Erba, Eleonora Castelletti, Vania Giacomet, Antonella Amendola, Elena Pariani, Elisabetta Tanzi, Mario Clerici

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

OBJECTIVE: It is unclear whether the ability to respond to vaccines is restored by antiretroviral therapy. We evaluated the influenza-specific immune responses elicited by a virosomal vaccine in HIV-infected children on long-term successful highly active antiretroviral therapy (HAART). METHODS: This was an observational, prospective, open-label study enrolling 24 HIV-infected, HAART-treated (85 months' mean exposure), vaccine-naive children (median age = 11.9 years) and 14 age- and gender-matched healthy controls. Mean CD4 T-cell counts (>900 cells/μL) and percentages (>37%) were comparable. The HIV RNA level was 40% of patients) and seroprotection (Ab titer ≥1:40 in >70% of patients) was achieved at 1 month in both groups; however, fewer HIV-infected children fulfilled these criteria. The A/H3N2- and A/H1N1-specific Ab geometric mean titers were lower in HIV-infected children compared with healthy controls at 1 and 6 months; interestingly, a boost in vaccine-specific IgG3 T helper 1 type Ab was seen in healthy controls alone. Finally, vaccine specific-IFNγ- and IL-2-producing T lymphocytes were reduced at both time points in HIV-infected children compared with healthy controls. CONCLUSIONS: One injection of virosomal-adjuvanted influenza vaccine stimulates good immune responses, although the humoral and cellular immune responses are reduced in HIV-infected children compared to healthy children. This indicates that immunologic function impairments may persist upon HIV infection even if HIV-positive viremia is suppressed and immune recovery seems to be achieved.

Original languageEnglish
Pages (from-to)289-296
Number of pages8
JournalJournal of Acquired Immune Deficiency Syndromes
Volume48
Issue number3
DOIs
Publication statusPublished - Jul 1 2008

Fingerprint

Influenza Vaccines
HIV
Vaccines
Highly Active Antiretroviral Therapy
Therapeutics
T-Lymphocytes
AIDS Vaccines
Viremia
CD4 Lymphocyte Count
Humoral Immunity
Cellular Immunity
Human Influenza
HIV Infections
Interleukin-2
Immunoglobulin G
RNA
Injections

Keywords

  • HIV infection
  • Immunology
  • Influenza
  • Pediatrics
  • Vaccine

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)
  • Virology
  • Immunology

Cite this

Humoral and cellular response to influenza vaccine in HIV-infected children with full viroimmunologic response to antiretroviral therapy. / Viganò, Alessandra; Zuccotti, Gian Vincenzo; Pacei, Michela; Erba, Paola; Castelletti, Eleonora; Giacomet, Vania; Amendola, Antonella; Pariani, Elena; Tanzi, Elisabetta; Clerici, Mario.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 48, No. 3, 01.07.2008, p. 289-296.

Research output: Contribution to journalArticle

Viganò, Alessandra ; Zuccotti, Gian Vincenzo ; Pacei, Michela ; Erba, Paola ; Castelletti, Eleonora ; Giacomet, Vania ; Amendola, Antonella ; Pariani, Elena ; Tanzi, Elisabetta ; Clerici, Mario. / Humoral and cellular response to influenza vaccine in HIV-infected children with full viroimmunologic response to antiretroviral therapy. In: Journal of Acquired Immune Deficiency Syndromes. 2008 ; Vol. 48, No. 3. pp. 289-296.
@article{ce9df7ec900b4475a3f032d215d4832e,
title = "Humoral and cellular response to influenza vaccine in HIV-infected children with full viroimmunologic response to antiretroviral therapy",
abstract = "OBJECTIVE: It is unclear whether the ability to respond to vaccines is restored by antiretroviral therapy. We evaluated the influenza-specific immune responses elicited by a virosomal vaccine in HIV-infected children on long-term successful highly active antiretroviral therapy (HAART). METHODS: This was an observational, prospective, open-label study enrolling 24 HIV-infected, HAART-treated (85 months' mean exposure), vaccine-naive children (median age = 11.9 years) and 14 age- and gender-matched healthy controls. Mean CD4 T-cell counts (>900 cells/μL) and percentages (>37{\%}) were comparable. The HIV RNA level was 40{\%} of patients) and seroprotection (Ab titer ≥1:40 in >70{\%} of patients) was achieved at 1 month in both groups; however, fewer HIV-infected children fulfilled these criteria. The A/H3N2- and A/H1N1-specific Ab geometric mean titers were lower in HIV-infected children compared with healthy controls at 1 and 6 months; interestingly, a boost in vaccine-specific IgG3 T helper 1 type Ab was seen in healthy controls alone. Finally, vaccine specific-IFNγ- and IL-2-producing T lymphocytes were reduced at both time points in HIV-infected children compared with healthy controls. CONCLUSIONS: One injection of virosomal-adjuvanted influenza vaccine stimulates good immune responses, although the humoral and cellular immune responses are reduced in HIV-infected children compared to healthy children. This indicates that immunologic function impairments may persist upon HIV infection even if HIV-positive viremia is suppressed and immune recovery seems to be achieved.",
keywords = "HIV infection, Immunology, Influenza, Pediatrics, Vaccine",
author = "Alessandra Vigan{\`o} and Zuccotti, {Gian Vincenzo} and Michela Pacei and Paola Erba and Eleonora Castelletti and Vania Giacomet and Antonella Amendola and Elena Pariani and Elisabetta Tanzi and Mario Clerici",
year = "2008",
month = "7",
day = "1",
doi = "10.1097/QAI.0b013e3181632cda",
language = "English",
volume = "48",
pages = "289--296",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Humoral and cellular response to influenza vaccine in HIV-infected children with full viroimmunologic response to antiretroviral therapy

AU - Viganò, Alessandra

AU - Zuccotti, Gian Vincenzo

AU - Pacei, Michela

AU - Erba, Paola

AU - Castelletti, Eleonora

AU - Giacomet, Vania

AU - Amendola, Antonella

AU - Pariani, Elena

AU - Tanzi, Elisabetta

AU - Clerici, Mario

PY - 2008/7/1

Y1 - 2008/7/1

N2 - OBJECTIVE: It is unclear whether the ability to respond to vaccines is restored by antiretroviral therapy. We evaluated the influenza-specific immune responses elicited by a virosomal vaccine in HIV-infected children on long-term successful highly active antiretroviral therapy (HAART). METHODS: This was an observational, prospective, open-label study enrolling 24 HIV-infected, HAART-treated (85 months' mean exposure), vaccine-naive children (median age = 11.9 years) and 14 age- and gender-matched healthy controls. Mean CD4 T-cell counts (>900 cells/μL) and percentages (>37%) were comparable. The HIV RNA level was 40% of patients) and seroprotection (Ab titer ≥1:40 in >70% of patients) was achieved at 1 month in both groups; however, fewer HIV-infected children fulfilled these criteria. The A/H3N2- and A/H1N1-specific Ab geometric mean titers were lower in HIV-infected children compared with healthy controls at 1 and 6 months; interestingly, a boost in vaccine-specific IgG3 T helper 1 type Ab was seen in healthy controls alone. Finally, vaccine specific-IFNγ- and IL-2-producing T lymphocytes were reduced at both time points in HIV-infected children compared with healthy controls. CONCLUSIONS: One injection of virosomal-adjuvanted influenza vaccine stimulates good immune responses, although the humoral and cellular immune responses are reduced in HIV-infected children compared to healthy children. This indicates that immunologic function impairments may persist upon HIV infection even if HIV-positive viremia is suppressed and immune recovery seems to be achieved.

AB - OBJECTIVE: It is unclear whether the ability to respond to vaccines is restored by antiretroviral therapy. We evaluated the influenza-specific immune responses elicited by a virosomal vaccine in HIV-infected children on long-term successful highly active antiretroviral therapy (HAART). METHODS: This was an observational, prospective, open-label study enrolling 24 HIV-infected, HAART-treated (85 months' mean exposure), vaccine-naive children (median age = 11.9 years) and 14 age- and gender-matched healthy controls. Mean CD4 T-cell counts (>900 cells/μL) and percentages (>37%) were comparable. The HIV RNA level was 40% of patients) and seroprotection (Ab titer ≥1:40 in >70% of patients) was achieved at 1 month in both groups; however, fewer HIV-infected children fulfilled these criteria. The A/H3N2- and A/H1N1-specific Ab geometric mean titers were lower in HIV-infected children compared with healthy controls at 1 and 6 months; interestingly, a boost in vaccine-specific IgG3 T helper 1 type Ab was seen in healthy controls alone. Finally, vaccine specific-IFNγ- and IL-2-producing T lymphocytes were reduced at both time points in HIV-infected children compared with healthy controls. CONCLUSIONS: One injection of virosomal-adjuvanted influenza vaccine stimulates good immune responses, although the humoral and cellular immune responses are reduced in HIV-infected children compared to healthy children. This indicates that immunologic function impairments may persist upon HIV infection even if HIV-positive viremia is suppressed and immune recovery seems to be achieved.

KW - HIV infection

KW - Immunology

KW - Influenza

KW - Pediatrics

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=47049113479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47049113479&partnerID=8YFLogxK

U2 - 10.1097/QAI.0b013e3181632cda

DO - 10.1097/QAI.0b013e3181632cda

M3 - Article

C2 - 18545155

AN - SCOPUS:47049113479

VL - 48

SP - 289

EP - 296

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 3

ER -